Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Gaya Anschuetz"'
Autor:
Gary A. Levy, Teresa L. Wright, Eugene R. Schiff, Jorge Rakela, Jules L. Dienstag, Robert P. Perrillo, Nathaniel A. Brown, Rolland C. Dickson, Paul Martin, Steve Bell, Lynn D. Condreay, Robert G. Gish, Paul C. Adams, Gaya Anschuetz
Publikováno v:
Hepatology. 33:424-432
Seventy-seven liver transplant candidates were enrolled in a multicenter study in which patients were treated with lamivudine (100 mg daily) without the adjunctive use of hepatitis B immune globulin. Treatment was begun while patients awaited liver t
Autor:
Gary Levy, Robert G. Gish, Eugene R. Schiff, Jules L. Dienstag, Gist H. Farr, Jean Pierre Villeneuve, Paul Martin, Nathaniel A. Brown, Lynn Crowther, Robert Perrillo, Stephen H. Caldwell, Jorge Rakela, Teresa L. Wright, Gaya Anschuetz
Publikováno v:
Hepatology. 29:1581-1586
Hepatitis B after liver transplantation is often fatal, and no proven medical therapy exists for this condition. We chose to study the potential efficacy of lamivudine therapy for patients with chronic hepatitis B after liver transplantation. Fifty-t
Autor:
Hie-Won L. Hann, Gregory T. Everson, Alfred L. Baker, Teresa L. Wright, Melanie Riker-Hopkins, Gaya Anschuetz, Eugene R. Schiff, Nathaniel Brown, Carolyn Riely, Robert J. Fontana
Publikováno v:
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 7(6)
Hepatitis B virus (HBV) infection after liver transplantation (LT) may lead to severe and rapidly progressive graft failure. Antiviral treatment may be of benefit in selected patients with recurrent hepatitis B post-LT. The aim of this prospective op
Autor:
Robert A. de Man, A. Ross Lopes, Rosa Maria Iemmolo, Mark Atkins, John O'Grady, Patrizia Burra, Roger Williams, Lucio Caccamo, Catherine A Barrett, Bernard Portmann, Margaret F. Bassendine, Nikolai V. Naoumov, Gaya Anschuetz
Publikováno v:
Journal of Hepatology, 34, 888-894. Elsevier
Background/Aims : The long-term prophylaxis of hepatitis B after liver transplantation requires further optimization. In a randomized trial we investigated a regimen where the initially given hepatitis B immunoglobulin (HBIg) is replaced by long-term
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12b01f0b58eb2b64d6369c53e084d058
https://pure.eur.nl/en/publications/2cc701e5-5b16-4ae1-9d5c-7d019b3d53cf
https://pure.eur.nl/en/publications/2cc701e5-5b16-4ae1-9d5c-7d019b3d53cf
Autor:
Andrew K. Burroughs, David Mutimer, Gaya Anschuetz, Leonie Grellier, Catherine Barrett, Monz Ahmed, Keith Rolles, Elwyn Elias, Amar P. Dhillon, Geoffrey Dusheiko, Stefan G. Hubscher
Publikováno v:
Transplantation. 70(5)
Background. This open, multicenter study was conducted to evaluate the efficacy and safety of lamivudine prophylaxis given to chronic hepatitis B virus(HBV) infected patients before and after orthotopic liver transplantation (OLT), We now present lon